Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it
PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participantsPH15 was safe and well-tolerated with an adverse
Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength
Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned
"Bezisterim" has been approved as the non-proprietary name for NE3107 Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammationCARSON CITY,
Altria Group beats expectations with a 2.5% year-on-year sales growth to $5.58 billion in Q1 FY24. Despite a decline in smokeable products revenue, gains in oral tobacco products and other segments offset the decrease. Altria's adjusted EPS of $1.15 meets forecasts.
Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161LEVEL UP, a Phase 3b/4
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced that it has received the Canadian Standards Association
CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 studyTop-line data